Date | Title |
---|
21/12/2020 | 18 Minutes with Zelira Therapeutics – 180 Markets |
16/11/2020 | The West Australian – Perth family describes their desperation when they sought cannabis for autistic, suicidal son |
05/11/2020 | OPINION | Reform should be driving protection for medicinal cannabis patients |
19/10/2020 | Cantor Fitzgerald Hosts Fireside Chat with Zelira Therapeutics |
29/09/2020 | Investor buzz around cannabis stocks with new treatments |
16/09/2020 | Zelira Therapeutics (ASX:ZLD) launches Zenivol in Australia |
16/09/2020 | Zelira Therapeutics’ insomnia treatment gets TGA tick |
16/09/2020 | Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme |
15/09/2020 | Medicinal cannabis trial could help retired AFL players manage chronic pain |
08/09/2020 | Zelira Therapeutics forms subsidiary to launch hemp-derived oral care products in the USA |
24/08/2020 | Proactive – Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers |
20/08/2020 | Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers |
19/08/2020 | Sequoia Initiation Research Report, 19 August 2020 |
17/08/2020 | Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation |
07/08/2020 | Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11 |
16/07/2020 | Starts at 60 – Suffer from chronic pain? Medicinal cannabis could be the answer |
14/07/2020 | TechInvest – Zelira obtains key data in cannabis dose escalation study |
14/07/2020 | The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated |
14/07/2020 | Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints |
14/07/2020 | Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial |